Nicole DeFeudis is an Editor at Endpoints News. She specializes in biopharma reporting, focusing on themes such as pharmaceuticals, healthcare administration, and public health. Nicole's work has been featured in New England Public Media, World Wealth Journal, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nicole's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly around regulatory approvals, legal policy regulation, and government announcements. She appears to be interested in stories related to FDA approvals, drug pricing, mergers and acquisitions within the pharmaceutical space.
To effectively reach out to Nicole with a pitch or as a source for her articles, it would be beneficial to provide insights or expertise related to recent developments in FDA regulations and approvals, legal challenges faced by pharmaceutical companies such as patent disputes or antitrust issues. Additionally, commentary on the implications of regulatory changes on drug pricing could also resonate well with her coverage focus.
It is important to note that Nicole tends to cover topics without geographic constraints explicitly mentioned. Therefore, pitches should focus on providing broader industry-specific insights rather than region-specific news unless otherwise indicated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights …
By: Nicole DeFeudis
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Nicole Defeudis
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April ...
By: Nicole Defeudis
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
By: Nicole Defeudis
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
By: Nicole DeFeudis
Customise Consent Preferences We use cookies to help you navigate efficiently and perform certain functions.
By: Nicole DeFeudis
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis' experimental CAR-T therapy. Novartis …
By: Nicole DeFeudis
Senior Reporter Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease.
FDA leaders in an NEJM article say they're open to innovative trial designs for psychedelic therapies, including non-placebo comparators.
By: Nicole Defeudis, Max Gelman
Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now that we’re past Labor Day. It will be a ...
